A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis

Trial Profile

A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Overactive bladder; Urinary incontinence
  • Focus Registrational; Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 31 Jan 2017 Results of post-hoc analysis (n=195) of patients who received only 200U dose of onabotulinumtoxinA during either of the two 52-week, phase 3 studies (NCT00311376 and NCT00461292) and the long-term extension study (NCT00876447), published in the BJU International journal.
    • 15 Apr 2016 Results of a pooled post-hoc analysis from this and other two trials (see profile 199731 and 199739) published in the Journal of Urology
    • 15 Apr 2014 Final results at 4 years presented at the 29th Congress of the European Association of Urology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top